4th Obesity & Weight Loss Drug Development Summit

📅 Tue, July 14, 2026 → Thu, July 16, 2026

Location: Hotel Commonwealth, 500 Commonwealth Avenue, Boston, MA 02215

About:

Now in its fourth year, the Obesity & Weight Loss Drug Development Summit has emerged as the industry-defining forum on advanced obesity therapeutics. The 2026 edition, hosted by Hanson Wade at Hotel Commonwealth in Boston, convenes 80+ senior scientists, clinical leaders, and commercial executives across preclinical, translational, and clinical development.

Programming spans mechanism diversification beyond GLP-1 — dual and triple agonists, amylins, siRNAs, oral small molecules, and mitochondrial approaches — alongside pediatric and geriatric clinical frameworks, protecting skeletal muscle quality during rapid weight loss, and the regulatory frontier around "quality of weight loss." The 2026 program features senior leaders from Novo Nordisk, Eli Lilly, Merck & Co., Roche, Rhythm, Veru, Canary Cure, and the leading emerging biotechs across triple-agonists, next-generation orals, and metabolic quality.

For senior leaders navigating cardiometabolic strategy — at pharma, biotech, or capital allocators evaluating the category — this is one of the most consequential focused summits of the summer.

🔗 Visit the official event site →

‍ ‍

Take your seat at the table. Apply to The Uplyft Collective →